Exelon (Rivastigmine) 1.5 mg / 3 mg / 4.5 mg / 6 mg Capsules and 4.6 mg–13.3 mg/24h Transdermal Patch: Prescription Dual Cholinesterase Inhibitor for Alzheimer’s and Parkinson’s Disease Dementia

Information last reviewed: May 2026 — for educational purposes only.

Exelon (rivastigmine tartrate) is a prescription dual-acting cholinesterase inhibitor that inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) — distinguishing it from donepezil and galantamine, which are selective for AChE only. This dual mechanism is theorised to provide broader cholinergic enhancement, particularly in later-stage Alzheimer's where BuChE activity increases relative to AChE as the disease progresses. Rivastigmine is FDA-approved for mild-to-moderate Alzheimer's dementia and, importantly, for dementia associated with Parkinson's disease — the only AChEI with explicit FDA approval for Parkinson's disease dementia (PDD).

Rivastigmine is available in oral capsules and a transdermal patch. The patch formulation is preferred clinically over capsules for most patients because transdermal delivery provides more stable plasma concentrations (avoiding the high peak plasma levels after oral dosing that are responsible for the GI side effects), achieving similar or better efficacy with significantly fewer GI adverse events. This makes the patch particularly valuable in frail elderly patients and those who experience intolerable GI side effects on oral rivastigmine or other oral AChEIs.

What Is Rivastigmine?

Rivastigmine is a slowly reversible ("pseudo-irreversible") carbamylating AChE and BuChE inhibitor. Unlike donepezil and galantamine (which are reversible competitive inhibitors), rivastigmine carbamylates the active site of cholinesterases — causing inhibition that persists until a new enzyme is synthesised by the body (~10 hours). This pseudoirreversible mechanism means rivastigmine must be dosed twice daily with oral capsules (to maintain coverage throughout the day), but the once-daily patch application maintains steady inhibition around the clock with minimal peak-to-trough fluctuation. BuChE is the predominant form of cholinesterase in Lewy body dementias (DLB and PDD), potentially explaining rivastigmine's particular effectiveness in these conditions compared to purely AChE-selective inhibitors.

Prescription Status

Rivastigmine is prescription-only in the United States. All dose forms — oral capsules and transdermal patches — require a physician prescription. For Parkinson's disease dementia, neurology or movement disorder specialist involvement is typical, though geriatricians and psychiatrists also prescribe it.

Strengths and Available Forms

• Oral capsules 1.5 mg, 3 mg, 4.5 mg, 6 mg — taken twice daily with food; start at 1.5 mg BID; increase by 1.5 mg per dose every minimum 2 weeks as tolerated; target: 3–6 mg BID; titration of capsules is more complex due to multiple dose levels and significant GI side effects
• Oral solution 2 mg/mL — for patients who cannot swallow capsules; same dosing schedule as capsules; can be mixed with cold water, fruit juice, or soda
• Transdermal patch 4.6 mg/24h — starting patch; apply once daily; delivers 4.6 mg rivastigmine over 24 hours (approximately equivalent to 3 mg BID oral); apply to upper back, upper arm, or chest — rotate sites daily; wear for 24 hours, replace next day at same time
• Transdermal patch 9.5 mg/24h — therapeutic maintenance patch; equivalent to approximately 6 mg BID oral; target maintenance patch for most patients
• Transdermal patch 13.3 mg/24h — highest strength patch; for moderate-severe Alzheimer's in patents stable on the 9.5 mg patch; approved specifically for this indication

Patch application guidelines: Apply to clean, dry, intact, hairless skin. Do not apply to irritated, red, or broken skin. Rotate patch sites to prevent skin irritation. Fold used patches in half (sticky sides together) and discard safely away from children and pets. Do not cut patches.

Price of Exelon Patch and Generic Rivastigmine

Generic rivastigmine capsules are available at low cost. Generic rivastigmine transdermal patches are also available and are significantly cheaper than brand-name Exelon patch. Even with the generic, patch forms are generally more expensive per day than generic tablets. Insurance typically covers both forms; prior authorisation may be needed for higher-strength patches. The 4.6 mg/9.5 mg starting/maintenance batch is widely covered.

Frequently Asked Questions

Why is rivastigmine the preferred choice for Parkinson's disease dementia?

Rivastigmine is the only AChEI with FDA approval specifically for Parkinson's disease dementia (PDD) — based on the landmark EXPRESS trial (2004), which demonstrated statistically and clinically significant improvements in cognition and global functioning in PDD patients on rivastigmine compared to placebo. Although donepezil is also used off-label for PDD with some supportive evidence, rivastigmine's BuChE inhibition may provide particular benefit in Lewy body dementias where BuChE-mediated degradation is prominent. In patients with both Parkinson's disease and cognitive impairment meeting criteria for PDD (cognitive symptoms developing >1 year after motor symptoms onset), rivastigmine is the evidence-based first-line pharmacological choice.

How does the transdermal patch reduce side effects compared to the oral capsules?

When rivastigmine capsules are absorbed orally, plasma concentrations rise sharply to a peak (Cmax) before declining between doses — creating a high-peak, low-trough pattern. The peak cholinergic stimulation of GI smooth muscle and the CTZ at these high Cmax levels causes nausea, vomiting, and diarrhoea. The transdermal patch eliminates these peaks, delivering rivastigmine through skin gradually at a near-constant rate — the steady plasma level provides continuous AChE/BuChE inhibition without the irritating peaks. Head-to-head studies comparing 9.5 mg/24h patch to 6 mg BID oral capsules showed equivalent cognitive efficacy but approximately 3-fold reduction in GI side effects with the patch. For patients who cannot tolerate oral AChEIs due to nausea, the patch is often very well tolerated.

What should be done if a rivastigmine patch falls off or is forgotten?

If a patch falls off during the day or a dose is forgotten, apply a new patch immediately and continue the regular once-daily schedule from that point. Do not apply two patches simultaneously under any circumstances — doubling the dose can cause excessive cholinergic stimulation, leading to severe nausea, vomiting, muscle weakness, bradycardia, or cholinergic crisis. After applying a new patch, continue alternating patch sites as normal. If more than one dose has been missed (multiple days), consult with the prescribing physician before re-starting — it may be necessary to re-titrate from a lower dose to avoid GI side effects after a gap in treatment.

← Back to Alzheimer Medications